1 vial


1 tablet


Diamox (Tab), Glaumox (Vial)

  1. Diuretic (particularly in the presence of metabolic alkalosis)

  2. Correction of severe metabolic alkalosis

PO / NG:
Diamox 250mg tablets (white); for NG use, crush prior to administration.

Glaumox is supplied as a sterile powder requiring reconstitution. Each vial contains an amount of acetazolamide sodium equivalent to 500 mg of acetazolamide.
Each 500-mg vial containing acetazolamide should be reconstituted with at least 5 ml of sterile water for injection prior to use. Reconstituted solutions retain their physical and chemical properties for 24 hours under refrigeration at 2-8°C or 12 hours at room temperature

For diuresis, the dose is usually 250-375 mg stat. If, after an initial response, the patient fails to continue to diurese, do not increase the dose but allow for kidney recovery by skipping medication for a day. Acetazolamide yields best diuretic results when given on alternate days, or for 2 days alternating with a day of rest.

The safety and effectiveness of acetazolamide in paediatric patients below the age of 12 years have not been established.

No dose adjustment is required when administered for ICU indications (beware that acetazolamide is contraindicated in the presence of metabolic acidosis).
This drug is not indicated in patients on renal replacement therapy.

Acetazolamide is an enzyme inhibitor that acts on carbonic anhydrase, the enzyme that catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid.


  1. Hypersensitivity to acetazolamide or other sulphonamides

  2. Metabolic acidosis

  3. Cirrhosis (risk of development of hepatic encephalopathy)

Fatalities have occurred, although rarely, due to severe reactions to acetazolamide including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias.

Increasing the dose does not increase the diuresis and may increase the incidence of drowsiness and/or paresthesia. Increasing the dose often results in a decrease in diuresis.

Laboratory Tests
No tests are required in addition to routine ICU blood tests.

Acetazolamide modifies phenytoin metabolism with increased serum levels of phenytoin.
Acetazolamide increases lithium excretion and the lithium levels may be decreased.
Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.
Acetazolamide may elevate cyclosporine levels.

Body as a Whole:
Headache, malaise, fatigue, fever, pain at injection site, flushing, flaccid paralysis, anaphylaxis.
Gastrointestinal disturbances such as nausea, vomiting, diarrhoea.
Hepato-Biliary Disorders:
Abnormal liver function, cholestatic jaundice, hepatic insufficiency, fulminant hepatic necrosis.
Metabolic acidosis, electrolyte imbalance, including hypokalaemia, hyponatraemia, loss of appetite, taste alteration, hyper/hypoglycemia.
Drowsiness, paresthesia (including numbness and tingling of extremities and face), depression, excitement, ataxia, confusion, convulsions, dizziness.
Allergic skin reactions including urticaria, photosensitivity, Stevens-Johnson syndrome
Special Senses:
Hearing disturbances, tinnitus, transient myopia.
Crystalluria, hematuria, glycosuria, renal failure polyuria.